Corsano

Greenberg Traurig Releases Asked & Answered: A Labor & Employment Law Podcast Episode 2

Retrieved on: 
Thursday, December 9, 2021
Equal Employment Opportunity Commission, Corsano, Carbon, EEOC, Workplace, Human rights, Journal of Employment Counseling, ADA, Civil Rights Act of 1964, Lawyer, Employment practices liability, Workforce, ADEA, LLP, Podcasts (software), OSHA, Employment, Performance, New York State Division of Human Rights, Special, Blog, U.S. Department of Labor, Office of Inspector General, GT, Trade secret, Greenberg Traurig, FLSA, Trade, Office of Inspector General, U.S. Department of Health and Human Services, Legislation, UNECE Environmental Performance Reviews, Topical steroid withdrawal, Industrial relations, Philippine Senate Committee on Labor, Employment and Human Resources Development, Equal opportunity, Sarbanes–Oxley Act, Insurance

Global law firm Greenberg Traurig, LLP has released the latest episode of its Asked & Answered podcast, "Return to Work and ADA Accommodation Requests."

Key Points: 
  • Global law firm Greenberg Traurig, LLP has released the latest episode of its Asked & Answered podcast, "Return to Work and ADA Accommodation Requests."
  • For insights and analysis of the latest labor and employment developments, including legislation, regulations, cases, policies, and trends, visit Greenberg Traurig's Labor & Employment blog and additional podcasts, The Performance Review: California Labor & Employment Podcast; The Workplace Safety Review Podcast (OSHA); and the Trade Secret Law Evolution Podcast.
  • About Greenberg Traurig's Labor & Employment Practice: Greenberg Traurig's Global Labor & Employment Practice serves clients from offices throughout the United States, Latin America, Europe, and Asia.
  • Visit Greenberg Traurig's Labor & Employment Blog for insights and analysis of the latest labor and employment developments, including legislation, regulations, cases, policies, and trends.

Corsano Health announces the publication of a new clinical validation study for its CardioWatch 287 in cardiac patients

Retrieved on: 
Tuesday, August 24, 2021
Medtech, Journal, Degenerative disease, ECG, Arrhythmia, Prognosis, Patient satisfaction, Diagnosis, CCN, RR, Sleep, Agreement, PPG, R, Elsevier, Marketing, DRS, Oxygen saturation (medicine), Heart rate, Patient, Compliance, CEO, HR, Journal of Electrocardiology, Corsano, Medical imaging, Medical device

BUSSUM, Netherlands, Aug. 24, 2021 /PRNewswire/ -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring devices announced the publication of a peer-reviewed clinical trial evaluating the accuracy of Heart Rate and RR Intervals measurements with its CardioWatch 287 wearable devices in 180 cardiac patients.

Key Points: 
  • Cardiology Centers Netherlands (CCN) investigated the accuracy of a state-of-the-art bracelet (Corsano CardioWatch 287) for heartbeat detection in cardiac patients and evaluated the efficacy of a signal qualifier in identifying medically useful signals.
  • The CCN study underscores that the Corsano CardioWatch 287 Bracelet with PPG-technology can determine HR and RR-intervals with high accuracy in cardiovascular at-risk patient population across different subgroups, especially with a signal quality indicator.
  • "The independent validation of Corsano Health's CardioWatch 287 is important evidence for our CE-MDR medical certification process.
  • "Additionally, the patient satisfaction survey conducted at the closure of the study cited convenience and ease to use of the CardioWatch 287 devices."

Corsano Health announces the publication of a new clinical validation study for its CardioWatch 287 in cardiac patients

Retrieved on: 
Tuesday, August 24, 2021
Medtech, Journal, Degenerative disease, ECG, Arrhythmia, Prognosis, Patient satisfaction, Diagnosis, CCN, RR, Sleep, Agreement, PPG, R, Elsevier, Marketing, DRS, Oxygen saturation (medicine), Heart rate, Patient, Compliance, CEO, HR, Journal of Electrocardiology, Corsano, Medical imaging, Medical device

Cardiology Centers Netherlands (CCN) investigated the accuracy of a state-of-the-art bracelet (Corsano CardioWatch 287) for heartbeat detection in cardiac patients and evaluated the efficacy of a signal qualifier in identifying medically useful signals.

Key Points: 
  • Cardiology Centers Netherlands (CCN) investigated the accuracy of a state-of-the-art bracelet (Corsano CardioWatch 287) for heartbeat detection in cardiac patients and evaluated the efficacy of a signal qualifier in identifying medically useful signals.
  • The CCN study underscores that the Corsano CardioWatch 287 Bracelet with PPG-technology can determine HR and RR-intervals with high accuracy in cardiovascular at-risk patient population across different subgroups, especially with a signal quality indicator.
  • "The independent validation of Corsano Health's CardioWatch 287 is important evidence for our CE-MDR medical certification process.
  • "Additionally, the patient satisfaction survey conducted at the closure of the study cited convenience and ease to use of the CardioWatch 287 devices."